Literature DB >> 10193281

Neonatal outcome and mode of delivery after epidural analgesia for labour with ropivacaine and bupivacaine: a prospective meta-analysis.

W D Writer1, R Stienstra, J M Eddleston, S P Gatt, R Griffin, B B Gutsche, T H Joyce, C Hedlund, K Heeroma, D Selander.   

Abstract

In this prospective meta-analysis, we have evaluated the effect of epidural analgesia with ropivacaine for pain in labour on neonatal outcome and mode of delivery compared with bupivacaine. In six randomized, double-blind studies, 403 labouring women, primigravidae and multiparae, received epidural analgesia with ropivacaine or bupivacaine 2.5 mg ml-1. The drugs were administered as intermittent boluses in four studies and by continuous infusion in two. Apgar scores, neurological and adaptive capacity scores (NACS), degree of motor block and mode of delivery were recorded. The studies were designed prospectively to fit meta-analysis of the pooled results. Results showed similar pain relief and consumption of the two drugs. In the vaginally delivered neonates, NACS scores were approximately equal for both groups at 2 h, but at 24 h there were fewer infants with NACS less than 35 in the ropivacaine compared with the bupivacaine group (2.8% vs 7.6%; P < 0.05). Spontaneous vaginal deliveries occurred more frequently overall with ropivacaine than with bupivacaine (58% vs 49%; P < 0.05) and instrumental deliveries (forceps and vacuum extraction) less frequently (27% vs 40%; P < 0.01), while the frequency of Caesarean section was similar between groups. The intensity of motor block was lower with ropivacaine. There were no significant differences in adverse events.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10193281     DOI: 10.1093/bja/81.5.713

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  17 in total

Review 1.  Ropivacaine: a review of its use in regional anaesthesia and acute pain management.

Authors:  Dene Simpson; Monique P Curran; Vicki Oldfield; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Epidural analgesia for childbirth: effects of newer techniques on neonatal outcome.

Authors:  Giorgio Capogna; Michela Camorcia
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 3.  Ropivacaine: an update of its use in regional anaesthesia.

Authors:  K J McClellan; D Faulds
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 4.  Benefit-risk assessment of ropivacaine in the management of postoperative pain.

Authors:  Wolfgang Zink; Bernhard M Graf
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Progress in analgesia for labor: focus on neuraxial blocks.

Authors:  J Sudharma Ranasinghe; David J Birnbach
Journal:  Int J Womens Health       Date:  2010-08-09

6.  No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA.

Authors:  John W Barrington; Roger H Emerson; Scott T Lovald; Adolph V Lombardi; Keith R Berend
Journal:  Clin Orthop Relat Res       Date:  2017-01       Impact factor: 4.176

Review 7.  Pain management for women in labour: an overview of systematic reviews.

Authors:  Leanne Jones; Mohammad Othman; Therese Dowswell; Zarko Alfirevic; Simon Gates; Mary Newburn; Susan Jordan; Tina Lavender; James P Neilson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

8.  The methodology for developing a prospective meta-analysis in the family planning community.

Authors:  David K Turok; Eve Espey; Alison B Edelman; Pamela S Lotke; Eva H Lathrop; Stephanie B Teal; Janet C Jacobson; Sara E Simonsen; Kenneth F Schulz
Journal:  Trials       Date:  2011-04-29       Impact factor: 2.279

9.  Ropivacaine: A review of its pharmacology and clinical use.

Authors:  Gaurav Kuthiala; Geeta Chaudhary
Journal:  Indian J Anaesth       Date:  2011-03

10.  Sequential methods for random-effects meta-analysis.

Authors:  Julian P T Higgins; Anne Whitehead; Mark Simmonds
Journal:  Stat Med       Date:  2010-12-28       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.